NHS funds eye gene therapy, after Novartis cuts £613,000 pri...

NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.

NICE lowers threshold for blood pressure drugs in new guidan...

Who could replace Sir Andrew Dillon at NICE?

With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health

After two decades taking on pharma over price, Sir Andrew Di...

After more than 20 years of challenging pharma over drug prices, Sir Andrew Dillon is to step down as NICE’s chief executive next year.

NICE’s track record in cancer drugs: the impact of the CDF a...

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.

MSD’s Keytruda plus chemo backed by NICE for lung cancer